FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
|Articles|April 1, 2011
- Pharmaceutical Technology-04-01-2011
- Volume 2011 Supplement
- Issue 2
Pharmaceutical Technology, April 2011 Solid Dosage Supplement (PDF)
Scrutinizing the Subvisible
Advertisement
Articles in this issue
over 15 years ago
Audio: Excipient Functionality and Continuous Manufacturingover 15 years ago
Exploring Excipient Functionalityover 15 years ago
Correlating Die-Filling Performance with Powder Propertiesover 15 years ago
Total Excipient Control: A Pathway to Increased Patient Safetyover 15 years ago
Innovations in Tablet Coatingover 15 years ago
Risk Assessment for Excipients for Enhanced Patient Safetyover 15 years ago
Exploring Nanotechnology in Drug Deliveryover 15 years ago
Oral-Absorption-Enhancing Drug-Delivery TechnologyAdvertisement
Related to this article
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5